BRAF V600E-mutant non-small-cell lung cancer: lines of therapy
3 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| BRAF | Advanced BRAF V600E, first line | Dabrafenib plus trametinib or encorafenib plus binimetinib (PHAROS); pembrolizumab with platinum doublet is an alternative, particularly with high PD-L1. | NCCN Guidelines: Non-Small Cell Lung Cancer | 98 | |
| BRAF | Advanced BRAF V600E, after targeted therapy | Pembrolizumab plus platinum doublet, or the other BRAF plus MEK pair if the first was stopped for toxicity rather than progression. | NCCN Guidelines: Non-Small Cell Lung Cancer | 98 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| BRAF | Non-V600 BRAF mutations | Treated as driver-negative disease with chemoimmunotherapy; MEK or pan-RAF inhibitor trials. | NCCN Guidelines: Non-Small Cell Lung Cancer | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.